Background/Objectives: Locoregional therapies (LRTs), including transarterial embolization (TAE), transarterial chemoembolization (TACE), and transarterial radioembolization (TARE), have become integral in the management of hepatocellular carcinoma (HCC) in recent decades and continue to shape evolving treatment strategies. While their role in liver tumor management is well established, their potential for treating extrahepatic malignancies is gaining increasing attention. Notably, growing research has highlighted the promising applications of TAE, TACE, and TARE in extrahepatic cancers such as glioblastoma (GBM), soft tissue sarcomas (STSs), prostate cancer (PCa), pancreatic cancer, and renal cell carcinoma (RCC). This review aims to explore these novel applications, providing a comprehensive summary of the current literature, examining clinical outcomes, and discussing future directions for integrating these techniques into broader oncologic treatment strategies. Methods: A systematic literature review was conducted focusing on LRTs such as TAE, TACE, and TARE in extrahepatic malignancies. Studies published between May 1998 and December 2024 were included, emphasizing outcomes in GBM, STS, PCa, pancreatic cancer, and RCC. Data extraction prioritized clinical outcomes, safety profiles, and procedural efficacy. Results: LRTs demonstrated significant potential in managing extrahepatic malignancies, with TAE, TACE, and TARE showing promising results in palliative management and tumor control. Across studies, these therapies exhibited varying degrees of success in improving progression-free survival and overall survival, with minimal systemic toxicity. Conclusions: The expanding application of LRTs in extrahepatic malignancies highlights their transformative potential in interventional oncology. By offering targeted, minimally invasive treatment options, these modalities bridge critical gaps in managing tumors refractory to conventional therapies. Future research should focus on standardizing protocols, optimizing patient selection, and exploring combination therapies to maximize their clinical efficacy.
**背景/目的：** 近几十年来，包括经动脉栓塞术、经动脉化疗栓塞术和经动脉放射栓塞术在内的局部区域疗法已成为肝细胞癌治疗中不可或缺的一部分，并持续影响着不断演变的治疗策略。虽然这些疗法在肝脏肿瘤治疗中的作用已得到公认，但其治疗肝外恶性肿瘤的潜力正日益受到关注。值得注意的是，越来越多的研究强调了TAE、TACE和TARE在肝外癌症，如胶质母细胞瘤、软组织肉瘤、前列腺癌、胰腺癌和肾细胞癌中的良好应用前景。本综述旨在探讨这些新颖的应用，全面总结现有文献，审视临床结果，并讨论将这些技术整合到更广泛肿瘤治疗策略中的未来方向。 **方法：** 针对TAE、TACE和TARE等LRT在肝外恶性肿瘤中的应用进行了系统性文献综述。纳入1998年5月至2024年12月期间发表的研究，重点关注其在GBM、STS、PCa、胰腺癌和RCC中的疗效。数据提取优先关注临床结果、安全性及手术疗效。 **结果：** LRT在治疗肝外恶性肿瘤方面显示出巨大潜力，TAE、TACE和TARE在姑息治疗和肿瘤控制方面均表现出良好效果。各项研究表明，这些疗法在改善无进展生存期和总生存期方面取得了不同程度的成功，且全身毒性极小。 **结论：** LRT在肝外恶性肿瘤中的扩展应用突显了其在介入肿瘤学领域的变革潜力。通过提供靶向、微创的治疗选择，这些方法弥补了治疗对常规疗法耐药的肿瘤方面的关键空白。未来的研究应侧重于标准化治疗方案、优化患者选择以及探索联合疗法，以最大化其临床疗效。
Expanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies
肿瘤(癌症)患者之家